{
    "organizations": [],
    "uuid": "2e302204c65ca424b81ebd50749bfc9eb0d96413",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-1nkemia-says-unit-leanbio-sets-up/brief-1nkemia-says-unit-leanbio-sets-up-jv-with-reig-jofre-idUSFWN1R80WQ",
    "ord_in_thread": 0,
    "title": "BRIEF-1nKemia Says Unit Leanbio Sets Up JV With Reig Jofre",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - 1NKEMIA IUCT GROUP SA:\n* SAYS UNIT LEANBIO AND REIG JOFRE SET UP JOINT VENTURE SYNA THERAPEUTICS TO DEVELOP BIOPHARMACEUTICAL PRODUCTS\n* SAYS LEANBIO TO HOLD 50 PERCENT IN JV * SAYS FOUNDING PARTNERS WILL CONTRIBUTE CAPITAL OF 9 MILLION EUROS TILL PHASE III OF CLINICAL DEVELOPMENT\nSource text: bit.ly/2ISWFyr\nFurther company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-26T23:21:00.000+03:00",
    "crawled": "2018-03-27T11:58:37.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "1nkemia",
        "iuct",
        "group",
        "sa",
        "say",
        "unit",
        "leanbio",
        "reig",
        "jofre",
        "set",
        "joint",
        "venture",
        "syna",
        "therapeutic",
        "develop",
        "biopharmaceutical",
        "product",
        "say",
        "leanbio",
        "hold",
        "percent",
        "jv",
        "say",
        "founding",
        "partner",
        "contribute",
        "capital",
        "million",
        "euro",
        "till",
        "phase",
        "iii",
        "clinical",
        "development",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}